Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Nifty extends winning streak to fifth day; banks, healthcare stocks lead gains
The S&P BSE Sensex advanced 254.36 points or 0.33% to 77,409.98. The Nifty 50 index rose 82.30 points or 0.34% to 24,168. In five sessions, the Sensex jumped 4.85% and Nifty climbed 4.35%.
Sun Pharmaceutical among 5 Nifty stocks showing bullish RSI upswing
Five Nifty50 stocks featured in the RSI Trending Up scan on June 17 after showing improving momentum. The RSI moved above the 50 mark from lower levels, signalling strengthening price action, improving sentiment and potential short-term buying opportunities for traders tracking bullish technical setups.
Godavari Biorefineries shares rises 10% on Japanese patent for cancer treatment invention
Godavari Biorefineries said the patented invention relates to the use of 5-Hydroxy-1,4-Naphthalenedione in the treatment of cancer and strengthens its intellectual property portfolio in the healthcare and life sciences space.
Nifty tops 23,850 as oil slump sparks broad-based rally
The key equity benchmark indices extended gains for a second consecutive session on Monday, supported by a sharp decline in crude oil prices and optimism surrounding a US-Iran peace agreement. Buying was broad-based, with most sectoral indices ending in the green. Investor sentiment was further buoyed by strong global cues, a stronger rupee and easing market volatility. The Nifty settled above the 23,850 mark, led by gains in consumer durables and auto stocks. However, pharma and healthcare shares bucked the trend and closed lower.
After Nestle, FSSAI Issues Notices To Eight Brands For Misleading Trade Names, Healthy Claims — Check Full List
FSSAI has issued notices to Emami Healthy & Tasty, Health Aid, Troovy, The Healthy Factory, Healthy Master, Healthy Choice, Plan B and Neuherbs.
AB Group reaffirms bet on Voda Idea with ₹4,730 Cr infusion
Vodafone Idea shareholders approved a ₹4,730-crore investment from the Aditya Birla Group via preferential allotment of warrants, increasing AB Group's stake to around 13%. Chairman Kumar Mangalam Birla stated the company's focus now shifts to execution across operations, customer service, and network expansion. This capital infusion will support capital expenditure and loan repayment, reinforcing Vi's financial health.
Analysts project up to 17% upside in healthcare stocks trading at new highs
Apollo Hospitals, Aster DM Healthcare, Sai Life Sciences have rallied up to 27% thus far in FY27; technical analysts remain bullish on these stocks given the favourable chart set-up.
Nifty 50 target cut by Citi to 26,000 - Key risk factors, top picks explained
Citi has highlighted Financials, Telecom, Healthcare, Defence and Utilities as their key "overweights", while IT Services, Staples, Metals are their top "underweights." It has also added Hitachi Energy into its list of top picks having initiated coverage on the stock recently.
Further consolidation ahead for Nifty? Here's today's outlook and top picks
Ajit Mishra of Religare Broking has recommended buying the shares of Fortis Healthcare, RBL Bank, and Eternal today
Market Trading Guide: Akums Drugs among 4 stock recommendations for Thursday
Domestic equities ended lower amid global uncertainty and caution ahead of key US inflation data. Despite market weakness, analysts remain bullish on Akums Drugs and Aditya Birla Sun Life AMC after strong technical breakouts, rising volumes and improving momentum indicators.
Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.